Rosetta Genomics Wins Two Key US Patent Allowances

Rosetta Genomics Ltd.

, a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company has received  two notices of allowance from the U.S. Patent and Trademark Office ("USPTO") for Patent Applications 12/661,041 and 12/850,091. The allowed claims of 12/661,041, entitled "microRNAs and Uses Thereof," cover the composition of matter for miR-29c*, as well as sequence variants (90% identical thereto), a vector and a probe comprising the same.  miR-29c* is a core element in the Company's lead commercial product, miRview^® mets^2 diagnostic assay for the identification of the tumor of origin in Cancer of Unknown and Uncertain Primary ("CUP").   The allowed claims of 12/850,091, entitled "Viral and Viral Associated MiRNAs and Uses Thereof," cover the composition of matter for herpes simplex virus 1 miR-H3, miR-H4 and miR-H5, as well as sequence variants (80% identical thereto), a vector and a complementary sequence comprising the same.